ACHIEVE LIFE SCIENCES, INC.

ACHV

ACHIEVE LIFE SCIENCES, INC.

ACHV

Insider Sentiment (TTM):

Last Purchase:2025-03-17Last Sale:2025-09-18Shares Purchased (TTM):0Shares Sold (TTM):381,972

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:21,491,189Shares Outstanding:53,381,989Institutional Ownership Pct.:40.26%

Earnings Market Reaction:

Filing Date:2026-05-12Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in In Vitro & In Vivo Diagnostic Substances

IDXX LNTH NEOG NTLA QDEL MYGN

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	28	21	32	52	13	13	10	15	66	16	20	25
Grants Receivable Current	-	-	-	-	-	-	-	-	-	0	0	0
Short Term Investments	-	-	-	-	-	-	33	47	-	-	-	-
Marketable Securities Current	1	15	16	4	10	22	-	-	-	-	-	-
Prepaid Expense And Other Assets Current	-	-	2	2	2	2	3	1	1	1	2	1
Assets Current	31	40	50	57	25	36	46	63	68	17	22	26
Assets Noncurrent
Operating Lease Right Of Use Asset	0	0	0	0	0	0	0	0	0	0	0	0
Finite Lived Intangible Assets Net	1	1	1	1	1	1	1	1	1	1	1	1
Goodwill	1	1	1	1	1	1	1	1	1	1	1	1
Assets	33	42	52	59	27	39	48	65	70	19	24	29
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	-	-	2	1	2	2	1	1	0	1	1	0
Other Accrued Liabilities Current	-	-	2	1	1	1	1	1	1	0	1	1
Business Combination Contingent Consideration Liab…	-	-	-	-	-	-	1	1	1	1	-	-
Employee Related Liabilities Current	2	2	2	2	1	3	2	1	1	2	2	1
Business Combination Contingent Consideration Liab…	0	2	1	1	-	0	-	-	-	1	-	-
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	0
Convertible Debt Current	6	4	1	1	1	-	-	9	17	17	-	-
Liabilities Current	12	9	10	9	7	7	7	14	21	21	4	3
Convertible Debt Noncurrent	9	11	9	9	9	10	10	9	-	-	16	16
Business Combination Contingent Consideration Liab…	1	0	0	0	1	1	-	-	-	-	-	-
Operating Lease Liability Noncurrent	-	0	0	0	0	0	-	-	-	0	0	0
Liabilities	22	20	18	17	17	18	17	23	21	21	20	19
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	281	282	279	273	229	226	224	223	222	164	164	163
Retained Earnings Accumulated Deficit	-270	-260	-246	-231	-218	-206	-193	-181	-172	-166	-160	-153
Accumulated Other Comprehensive Income Loss Net Of…	0	0	0	0	0	0	0	-0	0	0	0	0
Stockholders Equity	11	22	34	42	10	21	31	42	49	-1	4	10
Liabilities And Stockholders Equity	33	42	52	59	27	39	48	65	70	19	24	29
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	150	150	150	150	150	150	150	150	150	150	150	150
Common Stock Shares Issued	53	53	53	50	35	35	34	34	34	42	42	63
Shares Outstanding	53	53	53	50	35	35	34	34	34	42	42	63

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-14.36%	6.84%	-	-	-	-	-	-	-	-	-	-
2025	44.53%	-17.74%	-3.77%	12.88%	14.02%	89.39%	2.74%	-5.27%	18.14%	75.86%	82.41%	90.34%
2024	15.23%	3.75%	8.83%	-4.36%	15.14%	8.03%	-11.80%	-27.20%	-40.40%	-25.34%	-11.99%	22.60%
2023	-	-	-	-11.03%	-24.67%	-20.00%	39.38%	-1.67%	19.33%	-0.88%	9.89%	7.69%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	2.62	4.39	5.14	6.64	3.51	5.46	6.78	4.56	3.29	0.82	5.36	7.65
Quick Ratio	2.62	4.39	4.94	6.46	3.26	5.14	6.39	4.47	3.23	0.75	4.90	7.37
Working Capital	19.23M	30.81M	40.33M	48.33M	17.87M	29.79M	38.81M	48.82M	47.14M	-3.83M	17.82M	22.93M
Leverage & Debt
Debt to Equity	2.10	0.94	0.55	0.41	1.66	0.85	0.53	0.53	0.42	-14.38	5.03	1.98
Interest Coverage TTM	-58.26	-67.73	-69.43	-54.69	-30.74	-19.27	-12.89	-9.65	-9.83	-11.45	-14.61	-18.96
Debt Ratio	0.68	0.49	0.35	0.29	0.62	0.46	0.35	0.35	0.29	1.07	0.83	0.66
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-0.97	-1.25	-1.03	-1.45	-1.33	-1.24	-0.96	-0.80	-1.09	-1.50	-1.68	-2.18
Free Cash Flow Per Share TTM	-0.85	-1.13	-0.80	-1.15	-1.03	-0.93	-0.73	-0.57	-0.86	-1.24	-1.48	-1.96
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	12.63%	37.21%	58.90%	83.07%	68.98%	33.58%	-7.39%	-33.70%	-37.59%	-29.60%	-7.05%	30.29%
EPS Growth (1Y)	-26.82%	0.94%	7.00%	81.14%	22.03%	-17.42%	-43.05%	-63.20%	-55.35%	-24.77%	-14.70%	31.98%
Valuation Metrics
P/E TTM	-3.02	-3.96	-3.07	-1.55	-2.01	-2.83	-4.94	-5.86	-4.17	-2.74	-2.55	-2.38
P/B TTM	14.70	10.07	4.78	1.88	9.01	5.40	5.19	3.81	2.30	-56.41	22.50	10.19
Market Cap	156.94M	216.67M	160.71M	78.39M	92.61M	112.89M	162.84M	161.30M	113.97M	81.69M	90.85M	98.86M
Enterprise Value	143.77M	210.63M	138.65M	36.38M	89.44M	109.97M	163.12M	164.15M	64.71M	82.80M	87.12M	89.52M
Calculated Values
Free Cash Flow TTM	-45.31M	-49.47M	-40.68M	-39.72M	-35.57M	-29.77M	-24.95M	-19.73M	-21.49M	-24.50M	-31.27M	-37.43M
Net Debt	-13.18M	-6.04M	-22.05M	-42.01M	-3.17M	-2.92M	279.00K	2.85M	-49.26M	1.12M	-3.72M	-9.34M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-09-18Sale

Owner: Stewart, Richard Alistair

Title: Chief Executive Officer

Shares: 129,501

Price/Share: $2.92

Value: $378,142.92

Shares Owned: 228,875

Relationship: Director,Officer

Ownership: Direct

2025-09-18Sale

Owner: Oki, Mark K

Title: Chief Financial Officer

Shares: 50,060

Price/Share: $2.92

Value: $146,175.20

Shares Owned: 127,940

Relationship: Officer

Ownership: Direct

2025-09-04Sale

Owner: King, Thomas Braxton

Title: -

Shares: 139,858

Price/Share: $2.77

Value: $387,406.66

Shares Owned: 315,142

Relationship: Director

Ownership: Direct

2025-09-04Sale

Owner: Xinos, Jaime

Title: Chief Commercial Officer

Shares: 20,854

Price/Share: $2.77

Value: $57,765.58

Shares Owned: 74,432

Relationship: Officer

Ownership: Direct

2025-09-04Sale

Owner: Wan, Jerry

Title: Principal Accounting Officer

Shares: 14,070

Price/Share: $2.77

Value: $38,973.90

Shares Owned: 32,694

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-09-18	Stewart, Richard Alistair	Director,Officer	Chief Executive Officer	Direct	Sale	129,501	2.92	$378,142.92	228,875	4
2025-09-18	Oki, Mark K	Officer	Chief Financial Officer	Direct	Sale	50,060	2.92	$146,175.20	127,940	4
2025-09-04	King, Thomas Braxton	Director	-	Direct	Sale	139,858	2.77	$387,406.66	315,142	4
2025-09-04	Xinos, Jaime	Officer	Chief Commercial Officer	Direct	Sale	20,854	2.77	$57,765.58	74,432	4
2025-09-04	Wan, Jerry	Officer	Principal Accounting Officer	Direct	Sale	14,070	2.77	$38,973.90	32,694	4
2025-09-04	Jacobs, Cindy	Officer	President & CMO	Direct	Sale	27,629	2.77	$76,532.33	115,585	4
2025-03-17	Oki, Mark K	Officer	Chief Financial Officer	Direct	Purchase	10,000	2.89	$28,900.00	10,000	4
2025-03-17	Stewart, Richard Alistair	Director,Officer	Chieve Executive Officer	Direct	Purchase	10,000	2.86	$28,600.00	60,876	4
2024-03-04	Bencich, John	Director,Officer	CEO	Direct	Purchase	10,000	4.59	$45,900.00	76,724	4
2024-03-04	Stewart, Richard Alistair	Director,Officer	Executive Chairman	Direct	Purchase	10,000	4.59	$45,900.00	38,501	4
2023-05-30	Bencich, John	Director,Officer	CEO	Direct	Purchase	5,000	5.50	$27,500.00	66,730	4
2022-11-18	Bencich, John	Director,Officer	CEO	Direct	Purchase	22,000	-	-	36,920	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

40.26%

Inst. Shares: 21,491,189

Shares Outstanding: 53,381,989

2025-12-31

53.26%

Inst. Shares: 23,218,307

Shares Outstanding: 43,594,652

2025-09-30

30.40%

Inst. Shares: 15,508,037

Shares Outstanding: 51,017,662

2025-06-30

75.57%

Inst. Shares: 26,209,879

Shares Outstanding: 34,685,072

2025-03-31

41.29%

Inst. Shares: 14,320,010

Shares Outstanding: 34,685,072

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	21,491,189	53,381,989	40.26%
2025-12-31	23,218,307	43,594,652	53.26%
2025-09-30	15,508,037	51,017,662	30.40%
2025-06-30	26,209,879	34,685,072	75.57%
2025-03-31	14,320,010	34,685,072	41.29%
2024-12-31	16,247,890	32,071,146	50.66%
2024-09-30	16,857,552	34,355,050	49.07%
2024-06-30	18,530,922	34,318,709	54.00%
2024-03-31	16,435,743	25,048,134	65.62%
2023-12-31	16,230,330	19,827,354	81.86%
2023-09-30	17,814,540	21,127,281	84.32%
2023-06-30	20,436,312	19,048,627	107.28%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

ACHIEVE LIFE SCIENCES, INC. (ACHV) — SEC Financial Statements & Analysis

ACHIEVE LIFE SCIENCES, INC. (ACHV) is a in vitro & in vivo diagnostic substances company, incorporated in DE. ACHIEVE LIFE SCIENCES, INC. trades on ACHV: Nasdaq as: ACHV. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), ACHIEVE LIFE SCIENCES, INC. reported a Debt-to-Equity ratio of 2.10x, a Price-to-Book (P/B) ratio of 14.7 (TTM), at a market cap of $156.94M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 2.10x
P/B TTM: 14.7
Market Cap: $156.94M

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is ACHIEVE LIFE SCIENCES, INC. in?

ACHIEVE LIFE SCIENCES, INC. (ACHV) operates in the In Vitro & In Vivo Diagnostic Substances industry.

What is ACHV's market cap?

ACHIEVE LIFE SCIENCES, INC. (ACHV) has a market capitalization of $156.94M as of 2026-03-31.

What exchange does ACHV trade on?

ACHIEVE LIFE SCIENCES, INC. (ACHV) trades on the ACHV: Nasdaq.

Where is ACHIEVE LIFE SCIENCES, INC. incorporated?

ACHIEVE LIFE SCIENCES, INC. is incorporated in DE.

ACHIEVE LIFE SCIENCES, INC. (ACHV) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.